Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	144.71	69.33	75.05	93.12	203.43	288.64
Short-Term Investments	377.89	384.28	179.82	368.21	136.25	133.89
Cash & Short-Term Investments	522.6	453.61	254.87	461.33	339.68	422.53
Cash Growth	50.52%	77.98%	-44.75%	35.81%	-19.61%	21.74%
Receivables	140.83	142.08	144.16	165.5	148.93	140.88
Inventory	44.02	54.29	77.41	91.54	85.96	48.33
Prepaid Expenses	31.42	36.09	16.68	15.78	27.02	18.68
Total Current Assets	738.87	686.07	493.11	734.15	601.59	630.42
Property, Plant & Equipment	32.95	36.02	42.52	44.08	52.32	58.06
Long-Term Investments	-	-	16.62	93.9	119.17	350.36
Goodwill	117.02	117.02	117.02	117.02	117.52	77.91
Other Intangible Assets	481.31	521.91	599.89	702.46	784.69	364.34
Long-Term Deferred Tax Assets	6.18	-	-	-	-	-
Other Long-Term Assets	6.08	7.05	8.51	10.9	13.87	23.02
Total Assets	1,382	1,368	1,278	1,703	1,689	1,504
Accounts Payable	8.22	4.59	1.96	10.54	9.33	6.15
Accrued Expenses	197.03	180.21	166.26	185.67	199.47	165.62
Current Portion of Long-Term Debt	-	-	-	407.97	7.24	5.32
Current Portion of Leases	7.39	6.89	8.33	6.79	6.48	7.52
Other Current Liabilities	73.73	100.72	113.64	76.99	92.86	60.5
Total Current Liabilities	286.36	292.4	290.2	687.96	315.38	245.11
Long-Term Debt	-	-	-	-	385.23	375.16
Long-Term Leases	24.38	27.38	33.2	36	41.3	48.81
Long-Term Deferred Tax Liabilities	-	4.96	24.96	49.81	85.36	35.22
Other Long-Term Liabilities	7.76	7.6	7.8	42.54	46.04	54.95
Total Liabilities	318.51	332.34	356.16	816.3	873.3	759.24
Common Stock	0.06	0.06	0.06	0.05	0.05	0.05
Additional Paid-In Capital	496.95	479.44	439.49	408.12	434.34	409.33
Retained Earnings	567.1	556.43	482.56	481.25	379.92	326.5
Comprehensive Income & Other	-0.2	-0.19	-0.59	-3.21	1.54	8.98
Shareholders' Equity	1,064	1,036	921.52	886.2	815.85	744.86
Total Liabilities & Equity	1,382	1,368	1,278	1,703	1,689	1,504
Total Debt	31.77	34.27	41.53	450.76	440.25	436.82
Net Cash (Debt)	490.82	419.34	229.96	104.47	18.6	336.08
Net Cash Growth	59.77%	82.35%	120.12%	461.74%	-94.47%	-37.52%
Net Cash Per Share	8.69	7.49	4.14	1.69	0.34	6.26
Filing Date Shares Outstanding	56.07	55.81	54.73	54.38	53.39	52.92
Total Common Shares Outstanding	56.12	55.74	54.72	54.25	53.26	52.87
Working Capital	452.51	393.67	202.92	46.19	286.21	385.31
Book Value Per Share	18.96	18.58	16.84	16.33	15.32	14.09
Tangible Book Value	465.57	396.8	204.61	66.72	-86.36	302.61
Tangible Book Value Per Share	8.30	7.12	3.74	1.23	-1.62	5.72
Machinery	15.14	14.48	14.03	13.11	14.23	14.64
Construction In Progress	-	-	-	0.21	0.03	-
Leasehold Improvements	14.02	14.02	14.02	14.02	14.37	15.18

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q